Cargando…
Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study
BACKGROUND: In 2006, we reported the effectiveness of chemoradiotherapy for postoperative recurrent esophageal cancer with a median observation period of 18 months. The purpose of the present study was to update the results of radiotherapy combined with nedaplatin and 5-fluorouracil (5-FU) for posto...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518148/ https://www.ncbi.nlm.nih.gov/pubmed/23171077 http://dx.doi.org/10.1186/1471-2407-12-542 |
_version_ | 1782252524856672256 |
---|---|
author | Jingu, Keiichi Matsushita, Haruo Takeda, Ken Umezawa, Rei Takahashi, Chiaki Sugawara, Toshiyuki Kubozono, Masaki Abe, Keiko Tanabe, Takaya Shirata, Yuko Yamamoto, Takaya Ishikawa, Youjirou Nemoto, Kenji |
author_facet | Jingu, Keiichi Matsushita, Haruo Takeda, Ken Umezawa, Rei Takahashi, Chiaki Sugawara, Toshiyuki Kubozono, Masaki Abe, Keiko Tanabe, Takaya Shirata, Yuko Yamamoto, Takaya Ishikawa, Youjirou Nemoto, Kenji |
author_sort | Jingu, Keiichi |
collection | PubMed |
description | BACKGROUND: In 2006, we reported the effectiveness of chemoradiotherapy for postoperative recurrent esophageal cancer with a median observation period of 18 months. The purpose of the present study was to update the results of radiotherapy combined with nedaplatin and 5-fluorouracil (5-FU) for postoperative loco-regional recurrent esophageal cancer. METHODS: Between 2000 and 2004, we performed a phase II study on treatment of postoperative loco-regional recurrent esophageal cancer with radiotherapy (60 Gy/30 fractions/6 weeks) combined with chemotherapy consisting of two cycles of nedaplatin (70 mg/m(2)/2 h) and 5-FU (500 mg/m(2)/24 h for 5 days). The primary endpoint was overall survival rate, and the secondary endpoints were progression-free survival rate, irradiated-field control rate and chronic toxicity. RESULTS: A total of 30 patients were enrolled in this study. The regimen was completed in 76.7% of the patients. The median observation period for survivors was 72.0 months. The 5-year overall survival rate was 27.0% with a median survival period of 21.0 months. The 5-year progression-free survival rate and irradiated-field control rate were 25.1% and 71.5%, respectively. Grade 3 or higher late toxicity was observed in only one patient. Two long-term survivors had gastric tube cancer more than 5 years after chemoradiotherapy. Pretreatment performance status, pattern of recurrence (worse for patients with anastomotic recurrence) and number of recurrent lesions (worse for patients with multiple recurrent lesions) were statistically significant prognostic factors for overall survival. CONCLUSIONS: Radiotherapy combined with nedaplatin and 5-FU is a safe and effective salvage treatment for postoperative loco-regional recurrent esophageal cancer. However, the prognosis of patients with multiple regional recurrence or anastomotic recurrence is very poor. |
format | Online Article Text |
id | pubmed-3518148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35181482012-12-11 Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study Jingu, Keiichi Matsushita, Haruo Takeda, Ken Umezawa, Rei Takahashi, Chiaki Sugawara, Toshiyuki Kubozono, Masaki Abe, Keiko Tanabe, Takaya Shirata, Yuko Yamamoto, Takaya Ishikawa, Youjirou Nemoto, Kenji BMC Cancer Research Article BACKGROUND: In 2006, we reported the effectiveness of chemoradiotherapy for postoperative recurrent esophageal cancer with a median observation period of 18 months. The purpose of the present study was to update the results of radiotherapy combined with nedaplatin and 5-fluorouracil (5-FU) for postoperative loco-regional recurrent esophageal cancer. METHODS: Between 2000 and 2004, we performed a phase II study on treatment of postoperative loco-regional recurrent esophageal cancer with radiotherapy (60 Gy/30 fractions/6 weeks) combined with chemotherapy consisting of two cycles of nedaplatin (70 mg/m(2)/2 h) and 5-FU (500 mg/m(2)/24 h for 5 days). The primary endpoint was overall survival rate, and the secondary endpoints were progression-free survival rate, irradiated-field control rate and chronic toxicity. RESULTS: A total of 30 patients were enrolled in this study. The regimen was completed in 76.7% of the patients. The median observation period for survivors was 72.0 months. The 5-year overall survival rate was 27.0% with a median survival period of 21.0 months. The 5-year progression-free survival rate and irradiated-field control rate were 25.1% and 71.5%, respectively. Grade 3 or higher late toxicity was observed in only one patient. Two long-term survivors had gastric tube cancer more than 5 years after chemoradiotherapy. Pretreatment performance status, pattern of recurrence (worse for patients with anastomotic recurrence) and number of recurrent lesions (worse for patients with multiple recurrent lesions) were statistically significant prognostic factors for overall survival. CONCLUSIONS: Radiotherapy combined with nedaplatin and 5-FU is a safe and effective salvage treatment for postoperative loco-regional recurrent esophageal cancer. However, the prognosis of patients with multiple regional recurrence or anastomotic recurrence is very poor. BioMed Central 2012-11-22 /pmc/articles/PMC3518148/ /pubmed/23171077 http://dx.doi.org/10.1186/1471-2407-12-542 Text en Copyright ©2012 Jingu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Jingu, Keiichi Matsushita, Haruo Takeda, Ken Umezawa, Rei Takahashi, Chiaki Sugawara, Toshiyuki Kubozono, Masaki Abe, Keiko Tanabe, Takaya Shirata, Yuko Yamamoto, Takaya Ishikawa, Youjirou Nemoto, Kenji Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study |
title | Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study |
title_full | Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study |
title_fullStr | Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study |
title_full_unstemmed | Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study |
title_short | Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study |
title_sort | long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase ii study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518148/ https://www.ncbi.nlm.nih.gov/pubmed/23171077 http://dx.doi.org/10.1186/1471-2407-12-542 |
work_keys_str_mv | AT jingukeiichi longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy AT matsushitaharuo longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy AT takedaken longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy AT umezawarei longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy AT takahashichiaki longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy AT sugawaratoshiyuki longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy AT kubozonomasaki longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy AT abekeiko longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy AT tanabetakaya longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy AT shiratayuko longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy AT yamamototakaya longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy AT ishikawayoujirou longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy AT nemotokenji longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy |